Loratadine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Loratadine
Loratadine: Known uses and market status in Australia
Summary
Every candidate the TxGNN deep-learning model produced for Loratadine (score ≥ 0.99) that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use among the candidates is a relation recorded in the knowledge graph, not an approval.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| papillary conjunctivitis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 4313B | Claratyne | Tablet 10 mg | Valid |
Safety Considerations
Product Information warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Other relevant signals from the data compiled:
- Knowledge-graph contraindication associations (these come from a knowledge graph, not label text, and need verification against the PI): hypertension, liver and kidney disease or impaired renal function, gallbladder disease, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, coronary artery disease and atherosclerosis, angle-closure glaucoma, and hyperthyroidism (including Graves disease).
- Drug interactions: 100 interactions were identified in total. The main graded ones are:
- Moderate: glycerol phenylbutyrate, troglitazone
- Minor: clarithromycin, miconazole
- Many others are listed with an unknown severity level (for example metformin, omeprazole, morphine, doxycycline).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.